Loading…
Pharmaceuticals and Biotechnology · NSE · period ending 2026-03-31
Loading chart…
✓ Core business is permissible and non-compliant income is 0.52% of revenue (limit 5%).
| Ratio | Value | Limit | Result |
|---|---|---|---|
| Debt / 36-month avg market cap | 5.94% | < 33% | Pass |
| Cash + interest-bearing securities / 36-month avg market cap | 0.61% | < 33% | Pass |
| Accounts receivable / 36-month avg market cap | 2.11% | < 33% | Pass |
The underlying figures and the filing citations they came from are available with a free account.
Sign up free0.52% of any dividend from WOCKPHARMA should be given to charity. Calculate your amount →
Compliance watch: verdict re-verified against live market cap on 13 Jun 2026 · rechecked every 6 hours · filings reviewed quarterly.
WOCKPHARMA is in a very strong uptrend with large gains across all horizons and only a modest pullback from its 52-week high. High volatility and the 50-day SMA above the 200-day indicate a powerful but active trend.
Computed from delayed price history and desk sentiment. Educational context only — not investment advice or a price prediction.